NEW YORK, April 7, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2008 Fourth Quarter financial results before the U.S. stock market opens on Tuesday, April 15, 2008. Later that day, at 10:00 AM EDT, Forest will host a conference call where Dr. Lawrence Olanoff, President and Chief Operating Officer and Frank Perier, Senior Vice President and Chief Financial Officer, will discuss the financial results and relevant company and industry topics. The conference call will be webcast live beginning at 10:00 AM EDT on the Company's website http://www.frx.com and also on the website http://www.streetevents.com. Please log on to either website at least fifteen minutes prior to the conference call as it may be necessary to download software to access the call. A replay of the conference call will be available until April 30, 2008 at both websites and also by dialing 1-800-642-1687 (US investors) or +1-706-645-9291 (international investors), ID 42636974.
About Forest Laboratories and Its Products
Forest Laboratories is a US-based pharmaceutical company dedicated to
identifying, developing, and delivering products that make a positive
difference in peoples' lives. Forest Laboratories' growing product line
includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults
for the initial and maintenance treatment of major depressive disorder and
generalized anxiety disorder; Namenda(R) (memantine HCl), an
N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment
of moderate to severe Alzheimer's disease; Campral(R)* (acamprosate
calcium), indicated in combination with psychosocial support for the
maintenance of abstinence from alcohol in patients with alcohol dependence
who are abstinent at treatment initiation, and Bystolic(TM) (nebivolol), a
beta-adrenergic receptor blocking agent indicated for the treatment of
hypertension. In addition to our growing product line, Forest also
co-promotes the Daiichi Sankyo, Inc. product Azor(TM)* (amlodipine and
olmesartan medoxomil), a calcium channel blocker and angiotensin receptor
blocker combination product indicated for the treatment of hypertension.
For more information, visit http://www.frx.com.
* Azor is a trademark of Daiichi Sankyo, Inc. and Campral is a registered
trademark of Merck Sante s.a.s., a subsidiary of Merck KGaA, Darmstadt,
Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings.
|SOURCE Forest Laboratories, Inc.|
Copyright©2008 PR Newswire.
All rights reserved